Imedex: Education is the Best Medicine®

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

15th Annual Perspectives in Thoracic Oncology

November 19 - 20, 2010

New York, New York, United States

New York Marriott Downtown

Physicians
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 14.0 of AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Who Should Attend
This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pulmonologists, pathologists, and other healthcare providers involved and/or interested in the diagnosis, treatment, and management of patients with thoracic malignancies.

Objectives
After successful completion of this course, participants should be able to:

Describe one pathological issue regarding tissue acquisition and interpretation
Describe two current advances for the staging of patients with NSCLC
Discuss an optimal restaging approach for patients with stage IIIA disease and outline a treatment algorithm for patients with marginally operable early stage NSCLC
Evaluate the role of sterotactic radiotherapy, image-guided radiation therapy and prophylactic cranial irradiation therapy in NSCLC, and comment on a benefit and limitation of each
Recommend the most appropriate adjuvant therapy regimen for NSCLC
Recommend the most appropriate management strategies for small cell lung cancer, esophageal cancer, and bronchioloalveolar carcinoma
Outline the appropriate use of biomarkers, tumor histology and tumor molecular profiles guiding the therapeutic decision-making process
Discuss emerging data in terms of the standard of care in the untreated patient with advanced NSCLC
Evaluate the role of maintenance/consolidation therapy and salvage therapy in advanced NSCLC
Outline the most appropriate management strategy for elderly patients
Determine one appropriate management strategy to treat bone metastases and to prevent/minimize adverse events associated with chemotherapy such as nausea and vomiting
Evaluate the emerging role of targeted therapies as monotherapy and in combination with established regimens for the treatment of NSCLC

Chandra P. Belani, MD
Penn State Hershey Cancer Institute
Hershey, Pennsylvania

Jeffrey D. Bradley, MD
Washington University School of Medicine
St. Louis, Missouri

Roger B. Cohen, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Walter J. Curran, Jr., MD, FACP
Emory University School of Medicine
Atlanta, Georgia

Carolyn M. Dresler, MD
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Tracey L. Evans, MD
Abramson Cancer Center University of Pennsylvania
Wynnewood, Pennsylvania

Barbara Gitlitz, MD
USC Norris Comprehensive Cancer Center
Los Angeles, California

Richard J. Gralla, MD
Monter Cancer Center at the North Shore
LIJ Health System
Lake Success, New York

Paul J. Hesketh, MD
Lahey Clinic Medical Center
Burlington, Massachusetts

Fred R. Hirsch, MD, PhD
University of Colorado Cancer Center
Aurora, Colorado

Vira Hirsh, MD, FRCP
McGill University
Montreal, Quebec

David H. Ilson, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

James R. Jett, MD
Mayo Clinic
Rochester, Minnesota

Karen L. Kelly, MD
The University of Kansas Cancer Center
Kansas City, Kansas

John C. Kucharczuk, MD
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania

Corey J. Langer, MD, FACP
University of Pennsylvania
Philadelphia, Pennsylvania

Leslie A. Litzky, MD
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania

Vincent A. Miller, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Suresh S. Ramalingam
Winship Cancer Institute of Emory University
Atlanta, Georgia

Lecia V. Sequist, MD, MPH
Harvard Medical School
Boston, Massasuchetts

Gerard A. Silvestri, MD, MS
Medical University of South Carolina
Charleston, South Carolina

George R. Simon, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Friday, November 19, 2010

Session I: Introductory lectures

8:00 am
Welcome
Corey J. Langer, MD, FACP

8:10 am
Effects of tobacco on therapeutic outcome and prognosis: Rationale for treating tobacco dependence
Carolyn M. Dresler, MD

8:30 am
Lung cancer screening in 2010: Hope vs reality
James R. Jett, MD

8:50 am
Pathology: The critical issues in tissue acquisition and interpretation
Leslie A. Litzky, MD

9:10 am
Panel discussion and knowledge/confidence assessment of the audience via ARS survey

9:30 am
Break

Session II: Surgery and staging

9:50 am
Pre-activity knowledge/confidence assessment of the audience via ARS survey

9:55 am
The intricacies of staging in NSCLC
Gerard A. Silvestri, MD, MS

10:15 am
Restaging patients with stage IIIA NSCLC post-induction therapy: What is the optimal approach?
John C. Kucharczuk, MD

10:35 am
Debate: Surgery versus radiation therapy in marginally operable early stage NSCLC

Surgeon’s perspective:
Speaker Invited

Radiation oncologist’s perspective:
Jeffery D. Bradley, MD

11:05 am
Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

11:40 am
Luncheon Symposium
Supported by Lilly USA, LLC

Session III: Radiation oncology for the uninitiated and perpetually perplexed

12:55 pm
Pre-activity knowledge/confidence assessment of the audience via ARS survey

1:00 pm
Locally advanced unresectable NSCLC: State of the art and emerging therapies
Walter J. Curran, Jr., MD, FACR

1:20 pm
Stereotactic and image guided radiation therapy: Emerging role in localized lung cancer
Jeffery D. Bradley, MD

1:40 pm
The role of prophylactic cranial irradiation in SCLC and LA-NSCLC
Walter J. Curran, MD, FACR

2:00 pm
Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

Session IV: Adjuvant therapy

2:20 pm
Pre-activity knowledge/confidence assessment of the audience via ARS survey

2:25 pm
Adjuvant therapy: State of the art in 2010
Corey J. Langer, MD, FACP

2:55 pm
Ongoing clinical trials in the adjuvant arena
Tracey L. Evans, MD

3:15 pm
Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

3:35 pm
Break

Session V: Special topics in thoracic oncology

3:50 pm
Esophageal cancer: Therapeutic updates
David H. Ilson, MD

4:15 pm
SCLC: Challenges for an emerging orphan disease
Speaker Invited

4:40 pm
Revised classification of lung adenocarcinoma: What the clinician needs to know
Vincent A. Miller, MD

5:00 pm
Panel discussion and knowledge/confidence assessment of the audience via ARS survey

5:25 pm
Closing notes

5:30 pm
Adjourn

Saturday, November 20, 2010

8:00 am
Welcome to day two
Corey J. Langer, MD, FACP

Session VI: Advanced NSCLC

8:05 am
Pre-activity knowledge/confidence assessment of the audience via ARS survey

8:10 am
Role of histology in determining therapy in NSCLC
Chandra P. Belani, MD

8:30 am
Debate: An EGFR TKI should be used as first-choice therapy in EGFR mutation

Yes:
Lecia V. Sequist, MD, MPH

No:
Karen L. Kelly, MD

9:00 am
Has molecular determination MADe IT in 2010?
George R. Simon, MD

9:20 am
Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

9:40 am
Break

10:00 am
Pre-activity knowledge/confidence assessment of the audience via ARS survey

10:05 am
Debate: What is the optimal extended therapy approach? Maintenance/consolidation versus observation

Maintenance/consolidation:
Chandra P. Belani, MD

Observation:
Tracey L. Evans, MD

10:35 am
Salvage therapy in advanced NSCLC
Barbara Gitlitz, MD

10:55 am
Elderly with advanced NSCLC: Combating therapeutic nihilism in older patients
Corey J. Langer, MD, FACP

11:15 am
Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

Session VII: Supportive therapy

11:30 am
Quality of life: Neglected focus in lung cancer research
Richard J. Gralla, MD

11:50 am
Controlling chemotherapy induced nausea and vomiting
Paul J. Hesketh, MD

12:10 pm
Bone metastases: Expanding options?
Vira Hirsh, MD, FRCP

12:30 pm
Panel discussion and knowledge/confidence assessment of the audience via ARS survey

12:45 pm
Lunch

Session VIII: Targeted therapies

1:30 pm
Pre-activity knowledge/confidence assessment of the audience via ARS survey

1:35 pm
Angiogenesis inhibition: Bevacizumab and beyond
Suresh S. Ramalingam, MD

1:55pm
Reversing resistance to EGFR TKIs
Vincent A. Miller, MD

2:15 pm
Promising new therapies in NSCLC
Roger B. Cohen, MD

2:40 pm
Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

2:55 pm
Break

Session IX: Biomarkers

3:10 pm
Pre-activity knowledge/confidence assessment of the audience via ARS survey

3:15 pm
Looking beyond EGFR mutations: The role of proteomics and other biomarker proteomics
Fred R. Hirsch, MD, PhD

3:35 pm
Personalized therapy: The future has arrived
Speaker invited

3:55 pm
Panel discussion and post-activity knowledge/confidence assessment of the audience via ARS survey

4:15 pm
Closing notes
Corey J. Langer, MD, FACP

4:20 pm
Adjourn

$250 Discounted
Payment received by September 21, 2010

$350 Regular
Payment received by November 11, 2010

$450 Full/Onsite
Payment received after November 11, 2010

-$50 Group Discount (physicians only)*
Cannot be combined with any other discounts

$99 Nurses/Residents/Students*
Proof of eligibility must accompany registration; cannot be combined with any other discounts

To Register: You may register online by November 11, 2010 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Group Discounts: Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available for Nurses/Residents/Students.

Payment: To pre-register, registration and payment must be received no later than November 11, 2010. Please register onsite after this date. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda. Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

The Registration and Information Desk will be staffed:
Friday, November 19, 2010 7:00 am – 5:30 pm
Saturday, November 20, 2010 7:00 am – 5:00 pm

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than November 11, 2010. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after November 11, 2010.

New York Marriott Downtown
85 West Street at Albany Street
New York, New York 10006
Phone: 212-385-4900
Fax: 212-227-8136
www.nymarriottdowntown.com

For the convenience of attendees, a room block with a limited number of rooms has been reserved at the discounted group rate of $219 single/double occupancy, plus tax, currently at 14.75% plus a $3.50 occupancy tax. This limited number of discounted rooms will be available until October 29, 2010. This discounted rate is not guaranteed outside the conference dates. Reservations received after October 29, 2010 or after the room block has been filled (whichever comes first) are subject to availability and prevailing hotel rates.

To reserve your room please contact the New York Marriott Downtown reservations department at +1 (212) 385 4900 or visit the hotel’s website at www.nymarriottdowntown.com. To receive the group rate, callers must identify themselves as being with the Imedex/15th Annual Perspectives in Thoracic Oncology group. Reservation requests received after October 29, 2010 may not be guaranteed the group rate.

Dear Colleague,

Please join me in New York City this November for the 15th Annual Perspectives in Thoracic Oncology!

15 Years of Exceptional Educational Value: Perspectives in Thoracic Oncology has become the premier source for updates in thoracic oncology; we readily recognize the burgeoning need among thoracic oncology clinicians and researchers for the latest information on the complex biology and treatment of lung cancer. This conference provides a forum to update your knowledge in the field, confirm your current practice, and receive valuable take-home information on exciting new screening and staging modalities, management approaches, and emerging treatment options.

Significant Impact on Clinical Practice: Nearly 200 physicians, nurses, and other healthcare professionals attend Perspectives in Thoracic Oncology annually. Past participants value the scope and depth of the information on disease biology, management, and research presented, and many return year after year for the newest updates.

Distinguished Faculty and Networking Opportunities: In this educational setting, you will have valuable opportunities to interact with your colleagues and learn from renowned faculty, key thought leaders in thoracic oncology, as well as network with the diverse mix of oncologists, surgeons, and pulmonologists who attend.

This fall’s conference, to be held November 19-20, 2010, at the New York Marriott Downtown, promises to be our most exciting meeting yet. I hope to see you there!

Sincerely,
Corey J. Langer, MD, FACP
Chair

Organizer

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Quotes from Your Colleagues!

“Dr. Langer is a great moderator!”

“Very satisfied; continue current format”

“Superb and excellent conference!”

“Great variety of topics…continue with great work”

“Well run and comprehensive conference”

“Thanks, great conference;
continue what you are doing!”

“Excellent conference; good speakers”

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

The following companies have provided an educational grant in support of this conference:

PLATINUM

Genentech BioOncology
and OSI Oncology

GOLD

lilly

SILVER

lilly

BRONZE

EMD Sereno

CORPORATE

Daiichi-Sankyo

Several options are available to companies interested in supporting this conference.
For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.

Information coming soon.

The following companies are exhibitors at this conference:

Fujirebio

Lilly

Novartis Oncology

Prometheus

Response Genetics

Wolters Kluwer Health and Lippincott Williams and Wilkins

Click to download the Exhibitor Manual

Opportunities are available to companies interested in exhibiting at this conference.
For more information, please contact Cori Gunter at +1 (678) 242 0712, or by email at c.gunter@imedex.com.